JAMDA
Volume 8, Issue 5 , Pages 290-299 , June 2007

Clostridium difficile in the Long-Term Care Setting

  • Alex T. Makris, MD, CMD

      Affiliations

    • New Jersey American Medical Directors Association, Marlton, NJ
    • A.T.M. received an honorarium for his contributions to this article.
    • Corresponding Author InformationAddress correspondence to Alex T. Makris, MD, CMD, 532 Old Marlton Pike, PMC #195, Marlton, NJ 08053.
    • ,
  • Steven Gelone, PharmD

      Affiliations

    • ViroPharma Incorporated, Exton, PA
    • Department of Family, Community and Preventive Medicine, Drexel University College of Medicine, Philadelphia, PA.
    • S.G. is Director, Medical Affairs, of ViroPharma Pharmaceuticals, Incorporated.

References 

  1. Gerding DN. Disease associated with Clostridium difficile infection. Ann Intern Med. 1989;110:255–257
  2. McFarland LV, Stamm WE. Review of Clostridium difficile–associated diseases. Am J Infect Control. 1986;14:99–109
  3. Gerding DN, Olson MM, Peterson LR, et al. Clostridium difficile–associated diarrhea and colitis in adults: a perspective case-controlled epidemiologic study. Arch Intern Med. 1986;146:95–100
  4. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile–associated diarrhea and colitis (Practice Guidelines). Am J Gastroenterol. 1997;92:739–750
  5. Poutanen SM, Simor AE. Clostridium difficile–associated diarrhea in adults. CMAJ. 2004;171:51–58
  6. Bartlett JG. Antibiotic-associated diarrhea. N Engl J Med. 2002;346:334–339
  7. Mylonakis E, Ryan ET, Calderwood SB. Clostridium difficile–associated diarrhea: a review. Arch Intern Med. 2001;161:525–533
  8. Centers for Disease Control and Prevention (CDC). Fact Sheet. August 2004 (updated 07/22/05). Frequently Asked Questions. General Information about Clostridium difficile Infections. Available at: http://www.cdc.gov/ncidod/dhqp/id_CdiffFAQ_general.html. Accessed March 1, 2007.
  9. Simor AE, Bradley SF, Strausbaugh LJ, et al. The SHEA Long-Term Care Committee Clostridium difficile in long-term care facilities for the elderly (SHEA Position Paper). Infect Control Hosp Epidemiol. 2002;23:696–703
  10. Laffan AM, Bellantoni MF, Greenough WB, et al. Burden of Clostridium difficile–associated diarrhea in a long-term care facility. J Am Geriatr Soc. 2006;54:1068–1073
  11. Simor AE, Yake SL, Tsimidis K. Infection due to Clostridium difficile among elderly residents of a long-term-care facility. Clin Infect Dis. 1993;17:672–678
  12. Thomas DR, Bennett RG, Laughon BE, et al. Postantibiotic colonization with Clostridium difficile in nursing home patients. J Am Geriatr Soc. 1990;38:415–420
  13. Bender BS, Bennett R, Laughon BE, et al. Is Clostridium difficile endemic in chronic-care facilities?. Lancet. 1986;2:11–13
  14. Johnson S, Clabots CR, Linn FV, et al. Nosocomial Clostridium difficile colonisation and disease. Lancet. 1990;336:97–100
  15. Walker KJ, Gilliland SS, Vance-Bryan K, et al. Clostridium difficile colonization in residents of long-term care facilities: prevalence and risk factors. J Am Geriatr Soc. 1993;41:940–946
  16. Shim JK, Johnson S, Samore MH, Bliss DZ, Gerding DN. Primary symptomless colonization by Clostridium difficile and decreased risk of subsequent diarrhea. Lancet. 1998;351:633–666
  17. Johnson S, Homann SR, Bettin KM, et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole (A randomized, placebo-controlled trial). Ann Intern Med. 1992;117:297–302
  18. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996–2003. Emerg Infect Dis. 2006;12:409–415
  19. Dallal RM, Harbrecht BG, Boujoukas AJ, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg. 2002;235:363–372
  20. Pépin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile–associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ. 2005;173:1037–1042
  21. McDonald LC. Clostridium difficile: responding to a new threat from an old enemy. Infect Control Hosp Epidemiol. 2005;26:672–675
  22. Changing Demographics and the Implications for Physicians, Nurses, and Other Health Workers. US Department of Health and Human Services. Health Resources and Services, Administration Bureau of Health Professions. Available at: http://www.bhpr.hrsa.gov/healthworkforce/reports/changedmo/aging.htm. Accessed March 1, 2007.
  23. Johnson S, Gerding DN. Clostridium difficile–associated diarrhea. Clin Infect Dis. 1998;26:1027–1036
  24. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med. 2000;342:390–397
  25. Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect. 1998;40:1–15
  26. Tedesco FJ, Barton RW, Alpers DH. Clindamycin-associated colitis. Ann Intern Med. 1974;81:429–433
  27. Pear S, Williamson T, Bettin K, et al. Decrease in nosocomial Clostridium difficile–associated diarrhea by restricting clindamycin use. Ann Intern Med. 1994;120:272–277
  28. Loeb M, Simor AE, Landry L, et al. Antibiotic use in Ontario facilities that provide chronic care. J Gen Intern Med. 2001;16:376–383
  29. Montgomery P, Semenchuk M, Nicolle LE. Antimicrobial use in nursing homes in Manitoba. J Geriatr Drug Ther. 1995;9:55–74
  30. Lee YL, Thrupp LD, Nothvogel S, et al. Infection surveillance and antibiotic utilization in a community-based skilled nursing facility. Aging Clin Exp Res. 1996;8:113–122
  31. Mylotte JM. Measuring antibiotic use in a long-term care facility. Am J Infect Control. 1996;24:174–179
  32. Jacobson C, Strausbaugh LJ. Incidence and impact of infection in a nursing home care unit. Am J Infect Control. 1990;18:151–159
  33. Katz PR, Beam TR, Brand F, Boyce K. Antibiotic use in the nursing home (Physician practice patterns). Arch Intern Med. 1990;150:1465–1468
  34. McFarland LV, Surawicz CM, Stamm WE. Risk factors for Clostridium difficile carriage and Clostridium difficile–associated diarrhea in a cohort of hospitalized patients. J Infect Dis. 1990;162:678–684
  35. Thibault A, Miller MA, Gaese C. Risk factors for the development of Clostridium difficile–associated diarrhea during a hospital outbreak. Infect Control Hosp Epidemiol. 1991;12:34–48
  36. McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med. 1989;320:204–210
  37. Kim KH, Fekety R, Blatts DH, et al. Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. J Infect Dis. 1981;143:42–50
  38. Pierce PF, Wilson R, Silva J, et al. Antibiotic-associated pseudomembranous colitis: an epidemiologic investigation of a cluster of cases. J Infect Dis. 1982;145:269–274
  39. Al-Tureihi FI, Hassoun A, Wolf-Klein G, Isenberg H. Albumin, length of stay, and proton pump inhibitors: key factors in Clostridium difficile–associated disease in nursing home patients. J Am Med Dir Assoc. 2005;6:105–108
  40. Dial S, Delaney JAC, Barkun AN, Suissa S. Use of gastric-acid suppressive agents and the risk of community-acquired Clostridium difficile–associated disease. JAMA. 2005;294:2989–2995
  41. Pépin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile–associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41:1254–1260
  42. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005;353:2433–2441
  43. Stubbs S, Rupnik M, Gibert M, et al. Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile. FEMS Microbiol Lett. 2000;186:307–312
  44. Warny M, Pépin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005;366:1079–1084
  45. Centers for Disease Control and Prevention. Data and Statistics about Clostridium difficile Infections. Available at: http://www.cdc.gov/ncidod/dhqp/id_Cdiff_data.html. Accessed March 1, 2007.
  46. Gaynes R, Rimland D, Killum E, et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis. 2004;38:640–645
  47. Loo VG, Poirier L, Miller A, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile–associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353:2442–2449
  48. Muto CA, Pokrywka M, Shutt K, et al. A large outbreak of Clostridium difficile–associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol. 2005;26:273–280
  49. Pépin J, Alary M-E, Valiquette , et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis. 2005;40:1591–1597
  50. Linder JA, Huang ES, Steinman MA, et al. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med. 2005;118:259–268
  51. Valiquette L, Low DE, Pépin J, McGeer A. Clostridium difficile infection in hospitals: a brewing storm. CMAJ. 2004;171:27–29
  52. Loo VG, Libman MD, Miller MA, et al. Clostridium difficile: a formidable foe. Can Med Assoc J. 2004;171:47–48
  53. Pépin J, Valiquette L, Alary M-E, et al. Clostridium difficile–associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ. 2004;171:466–472
  54. Wanahita A, Goldsmith EA, Marino BJ, Musher DM. Clostridium difficile infection in patients with unexplained leukocytosis. Am J Med. 2003;115:543–546
  55. Sunenshine RH, McDonald LC. Clostridium difficile–associated disease: new challenges from an established pathogen. Cleveland Clin J Med. 2006;73:187–197
  56. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med. 1994;330:257–262
  57. Wilkins TD, Lyerly DM. Clostridium difficile testing: after 20 years, still challenging. J Clin Microbiol. 2003;41:531–534
  58. Walker RC, Ruane PJ, Rosenblatt JE, et al. Comparison of culture, cytotoxicity assays, and enzyme-linked immunosorbent assay for toxin A and toxin B in the diagnosis of Clostridium difficile–related enteric disease. Diagn Microbiol Infect Dis. 1986;5:61–69
  59. Borek AP, Aird DZ, Carroll KC. Frequency of sample submission for optimal utilization of the cell culture cytotoxicity assay for detection of Clostridium difficile toxin. J Clin Microbiol. 2005;43:2994–2995
  60. Ticehurst JR, Aird DZ, Dam LM, et al. Effective detection of toxigenic Clostridium difficile by a two-step algorithm including tests for antigen and cytotoxin. J Clin Microbiol. 2006;44:1145–1149
  61. Gerding DN, Johnson S, Peterson LR, et al. Clostridium difficile–associated diarrhea and colitis (SHEA Position Paper). Infect Control Hosp Epidemiol. 1995;16:459–477
  62. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile–associated disease: old therapies and new strategies. Lancet Infect Dis. 2005;5:549–557
  63. American Society of Health-System Pharmacists. Therapeutic Position Statement on the preferential use of metronidazole for the treatment of Clostridium difficile–associated disease. Am J Health-Syst Pharm. 1998;55:1407–1411
  64. Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis. 2005;40:1586–1590
  65. Wilcox MH, Howe R. Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin. J Antimicrob Chemother. 1995;36:673–699
  66. Zar FA, et al. Vancomycin (V) is superior to metronidazole (M) in the treatment of severe Clostridium difficile–associated diarrhea (CDAD). 2006;Paper presented at: 44th Annual Meeting of the Infectious Diseases Society of America (IDSA); October 12–15; Toronto, Canada: Abstract 686
  67. Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance (Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC)). MMWR Recomm Rep. 1995;44:1–13
  68. Gerding DN. Is there a relationship between vancomycin-resistant enterococcal infection and Clostridium difficile infection?. Clin Infect Dis. 1997;25(Suppl 2):S206–S210
  69. Salgado CD, Giannetta ET, Farr BM. Failure to develop vancomycin-resistant Enterococcus with oral vancomycin treatment of Clostridium difficile. Infect Control Hosp Epidemiol. 2004;25:413–417
  70. Donskey CJ, Chowdhry TK, Hecker MT, et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med. 2000;343:1925–1932
  71. The Medical Letter on Drugs and Therapeutics (Treatment of Clostridium difficile–associated disease (CDAD)). Med Lett. 2006;48:89–91
  72. Kleinfeld DI, Sharpe RJ, Donta ST. Parenteral therapy for antibiotic-associated pseudomembranous colitis. J Infect Dis. 1988;157:389
  73. Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut. 1986;27:1169–1172
  74. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol. 2002;97:1769–1775
  75. McFarland LV. Alternative treatments for Clostridium difficile disease: what really works?. J Med Microbiol. 2005;54:101–111
  76. Fernandez A, Anand G, Friedenberg F. Factors associated with failure of metronidazole in Clostridium difficile–associated disease. J Clin Gastroenterol. 2004;38:414–418
  77. Tedesco FJ, Gordon D, Fortson WC. Approach to patients with multiple relapses of antibiotic-associated pseudomembraneous colitis. Am J Gastroenterol. 1985;80:867–868
  78. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA. 1994;271:1913–1918
  79. Surawicz CM, McFarland LV, Greenberg LN, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis. 2000;31:1012–1017
  80. Dendukuri N, Costa V, McGregor M, Brophy JM. Probiotic therapy for the prevention and treatment of Clostridium difficile–associated diarrhea: a systematic review. CMAJ. 2005;173:167–170
  81. Wilcox MH. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J Antimicrob Chemother. 2004;53:882–884
  82. McPherson S, Rees CJ, Ellis R, et al. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum. 2006;49:640–645
  83. Cavagnaro C, Berezin S, Medow MS. Corticosteroid treatment of severe, non-responsive Clostridium difficile induced colitis. Arch Dis Child. 2003;88:342–344
  84. Apisarnthanarak A, Razavi B, Mundy LM. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis. 2002;35:690–696
  85. Buggy BP, Fekety R, Silva J. Therapy of relapsing Clostridium difficile–associated diarrhea and colitis with the combination of vancomycin and rifampin. J Clin Gastroenterol. 1987;9:155–159
  86. Lagrotteria D, Holmes S, Smieja M, et al. Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile–associated diarrhea. Clin Infect Dis. 2006;43:547–552
  87. Aas J, Gessert CE, Bakken JS, et al. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis. 2003;36:580–585
  88. Bartlett JG, Perl TM. The new Clostridium difficile—what does it mean?. N Engl J Med. 2005;353:2503–2505
  89. Mayfield JL, Leet T, Miller J, Mundy LM. Environmental control to reduce transmission of Clostridium difficile. Clin Infect Dis. 2000;31:995–1000
  90. Kaatz GW, Gitlin SD, Schaberg DR, et al. Acquisition of Clostridium difficile from the hospital environment. Am J Epidemiol. 1988;127:1289–1294
  91. Wilcox MH, Fawley WN, Wigglesworth N, et al. Comparison of the effect of detergent versus hypochlorite cleaning on environmental contamination and incidence of Clostridium difficile infection. J Hosp Infect. 2003;54:109–114
  92. Davey P, Brown E, Fenelon L, et al. Systematic review of antimicrobial drug prescribing in hospitals. Emerg Infect Dis. 2006;12:211–216
  93. Carling P, Fung T, Killion A, Terrin N, Barza M. Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol. 2003;24:699–706
  94. Climo MW, Israel DS, Wong ES, et al. Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile–associated diarrhea and cost. Ann Intern Med. 1998;128:989–995
  95. Khan R, Cheesbrough J. Impact of changes in antibiotic policy on Clostridium difficile–associated diarrhea (CDAD) over a five-year period in a district general hospital. J Hosp Infect. 2003;54:104–108
  96. McNulty C, Logan M, Donald IP, et al. Successful control of Clostridium difficile infection in an elderly care unit through use of a restrictive antibiotic policy. J Antimicrob Chem. 1997;40:707–711
  97. Ho M, Yang D, Wyle FA, Mulligan ME. Increased incidence of Clostridium difficile–associated diarrhea following decreased restriction of antibiotic use. Clin Infect Dis. 1996;23(Suppl 1):S102–S106

 This work was supported by an educational grant from ViroPharma Pharmaceuticals, Inc.

PII: S1525-8610(07)00127-2

doi: 10.1016/j.jamda.2007.01.098

JAMDA
Volume 8, Issue 5 , Pages 290-299 , June 2007

Article Tools

* Image Usage & Resolution